<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04401852</url>
  </required_header>
  <id_info>
    <org_study_id>60</org_study_id>
    <nct_id>NCT04401852</nct_id>
  </id_info>
  <brief_title>Magnesium Sulfate for Fetal Neuroprotection</brief_title>
  <official_title>Magnesium Sulphate for Fetal Neuroprotection in Full Term Deliveries</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cairo University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cairo University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pregnant women diagnosed to have intrapartum fetal distress (Non reassuring or pathological&#xD;
      changes according to NICE guidelines 2017) in any of the groups will receive the allocated&#xD;
      treatment at least 20 minute before the procedure (emergency CS).&#xD;
&#xD;
      measures to reduce the effect of hypoxia will be applied to all participate through:&#xD;
&#xD;
        -  The position of the mother will be changed to left lateral position (allow increased&#xD;
           blood supply).&#xD;
&#xD;
        -  I.V. fluid bolus (to avoid maternal dehydration).&#xD;
&#xD;
        -  Oxytocin or cervical ripening agent will be discontinued.&#xD;
&#xD;
        -  Fetal heart rate monitoring with cardiotocography will be attempted.&#xD;
&#xD;
        -  If umbilical cord prolapse is noted, elevate the presenting fetal part until preparing&#xD;
           for emergency operative delivery.&#xD;
&#xD;
        -  After birth, Apgar score will be used to identify distress newborns that need&#xD;
           resuscitation.&#xD;
&#xD;
      The study comprised 200 pregnant women. They were divided into two groups each are 100:&#xD;
&#xD;
        -  Group A: pregnant women diagnosed to have intrapartum fetal distress who will receive&#xD;
           MgSO4.&#xD;
&#xD;
        -  Group B: pregnant women diagnosed to have intrapartum fetal distress who will receive&#xD;
           placebo&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pregnant women diagnosed to have intrapartum fetal distress (Non reassuring or pathological&#xD;
      changes according to NICE guidelines 2017) in any of the groups will receive the allocated&#xD;
      treatment at least 20 minute before the procedure (emergency CS).&#xD;
&#xD;
      measures to reduce the effect of hypoxia will be applied to all participate through:&#xD;
&#xD;
        -  The position of the mother will be changed to left lateral position (allow increased&#xD;
           blood supply).&#xD;
&#xD;
        -  I.V. fluid bolus (to avoid maternal dehydration).&#xD;
&#xD;
        -  Oxytocin or cervical ripening agent will be discontinued.&#xD;
&#xD;
        -  Fetal heart rate monitoring with cardiotocography will be attempted.&#xD;
&#xD;
        -  If umbilical cord prolapse is noted, elevate the presenting fetal part until preparing&#xD;
           for emergency operative delivery.&#xD;
&#xD;
        -  After birth, Apgar score will be used to identify distress newborns that need&#xD;
           resuscitation.&#xD;
&#xD;
      The study comprised 200 pregnant women. They were divided into two groups each are 100:&#xD;
&#xD;
        -  Group A: pregnant women diagnosed to have intrapartum fetal distress who will receive&#xD;
           MgSO4.&#xD;
&#xD;
        -  Group B: pregnant women diagnosed to have intrapartum fetal distress who will receive&#xD;
           placebo&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 21, 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Apgar score</measure>
    <time_frame>1 minute after delivery</time_frame>
    <description>Apgar stands for &quot;Appearance, Pulse, Grimace, Activity, and Respiration between 0 and 10</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Fetal Neuroprotection</condition>
  <arm_group>
    <arm_group_label>MgSO4 group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>will receive a single bolus dose of 4g MgSO4 slowly intravenous over 15-20 minutes without maintenance dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>will receive an equal volume of isotonic 0.9% saline over 15-20 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MgSo4</intervention_name>
    <description>a single bolus dose of 4g MgSO4 slowly intravenous over 15-20 minutes without maintenance dose.</description>
    <arm_group_label>MgSO4 group</arm_group_label>
    <other_name>magnesium sulfate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotonic saline</intervention_name>
    <description>equal volume of isotonic 0.9% saline over 15-20 minutes</description>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Pregnant women at least 37 week of gestation.&#xD;
&#xD;
          -  Not more than 35 years old.&#xD;
&#xD;
          -  Fetal distress (perinatal asphyxia) diagnosed by CTG changes (Non reassuring or&#xD;
             pathological changes according to NICE guidelines 2017).&#xD;
&#xD;
          -  Clinical chorioamnionitis.&#xD;
&#xD;
          -  Prolonged rupture of membranes&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medical disorders such as chronic hypertension, preeclampsia, eclampsia, DM, pulmonary&#xD;
             hypertension, hepatic coma with risk of renal failure, and any renal, cardiac or&#xD;
             pulmonary disease.&#xD;
&#xD;
          -  RH -ve.&#xD;
&#xD;
          -  Consanguinity.&#xD;
&#xD;
          -  Preterm labor.&#xD;
&#xD;
          -  Fetal malpresentation.&#xD;
&#xD;
          -  Contraindications to the use of Magnesium Sulphate.&#xD;
&#xD;
          -  Any indication for magnesium Sulphate therapy (seizure prophylaxis or tocolysis).&#xD;
&#xD;
          -  Myasthenia gravis.&#xD;
&#xD;
          -  Congenital fetal anomalies.&#xD;
&#xD;
          -  Fetal growth restriction (birth weight &lt; 10th Percentile for gestational age).&#xD;
&#xD;
          -  Advanced cervical dilation (8cm).&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ahmed maged</last_name>
    <phone>+201005227404</phone>
    <email>ahmedmaged@cu.edu.eg</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Wesam Deeb</last_name>
    <email>wessamdeeb74@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kasr Alainy medical school</name>
      <address>
        <city>Cairo</city>
        <zip>12151</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ahmed Maged, MD</last_name>
      <phone>01005227404</phone>
      <email>prof.ahmedmaged@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>May 21, 2020</study_first_submitted>
  <study_first_submitted_qc>May 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 26, 2020</study_first_posted>
  <last_update_submitted>February 5, 2021</last_update_submitted>
  <last_update_submitted_qc>February 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Cairo University</investigator_affiliation>
    <investigator_full_name>Ahmed M Maged, MD</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Sulfate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

